Adare has acquired Frontida BioPharm that is a vertically integrated CDMO focused on oral formulations
Adare Pharma Solutions, a technology-driven contract development and manufacturing organisation (CDMO), has announced the acquisition of Frontida BioPharm, a vertically integrated CDMO focused on oral formulations.
The acquisition reinforces Adare's commitment to transform drug delivery from product development through commercial-scale manufacturing and packaging. Adare's portfolio of offerings for its customers will expand to include new capabilities such as high potency compound handling and packaging services.
The combined company will lead in the space of oral formulations
Vivek Sharma, CEO of Adare, said: "The combined company will lead in the space of oral formulations, while expanding the services and technical offerings we provide to meet the needs of our customers and their patients."
"We are very excited about the opportunities this transaction is expected to provide to both existing and new clients," Song Li, Frontida's Chairman, added. "Our combined resources and capabilities will result in enhanced support and talent to ensure the success of their development and commercialisation programmes. We look forward to continuing our work together to provide innovative, life-enhancing products to the US and global markets."
Together, the combined company will offer an expanded suite of solutions for complex oral formulations, such as taste masking, controlled release, high potency formulation manufacturing, and bioavailability enhancement. The addition of Frontida brings Adare's manufacturing footprint to seven sites globally and expands Adare's integrated, end-to-end offering to its partners. The combined organisation will be led by Vivek Sharma.